Metagenomi Therapeutics, Inc. SEC filings MGX
Metagenomi Therapeutics, Inc. has 154 filings in SEC EDGAR's recent list, going back to Aug 16, 2019. Its latest annual report, Form ARS, was filed on Apr 27, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Aug 10, 2026, covering the quarter ended Jun 30, 2026. The most recent current report (Form 8-K) was filed on Sep 22, 2026 (regulation fd disclosure). The company's fiscal year ends on December 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Regulation FD disclosure
|
Sep 22, 2026 | Sep 21, 2026 |
| 4 | Insider transaction | Sep 11, 2026 | Sep 9, 2026 |
| SCHEDULE 13G | Ownership over 5% (passive) | Sep 10, 2026 | — |
| 4 | Insider transaction | Sep 10, 2026 | Sep 8, 2026 |
| 4 | Insider transaction | Sep 10, 2026 | Sep 8, 2026 |
| 4 | Insider transaction | Sep 10, 2026 | Sep 8, 2026 |
| 10-Q | Quarterly report | Aug 10, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Results of operations
|
Aug 10, 2026 | Aug 10, 2026 |
| 4 | Insider transaction | Jun 11, 2026 | Jun 9, 2026 |
| 4 | Insider transaction | Jun 11, 2026 | Jun 9, 2026 |
| 4 | Insider transaction | Jun 11, 2026 | Jun 9, 2026 |
| 4 | Insider transaction | Jun 11, 2026 | Jun 9, 2026 |
| 4 | Insider transaction | Jun 10, 2026 | Jun 5, 2026 |
| 4 | Insider transaction | Jun 10, 2026 | Jun 5, 2026 |
| 4 | Insider transaction | Jun 10, 2026 | Jun 5, 2026 |
| 8-K |
Current report
Officer or director change, Shareholder vote results
|
Jun 10, 2026 | Jun 9, 2026 |
| 10-Q | Quarterly report | May 11, 2026 | Mar 31, 2026 |
| 8-K |
Current report
Results of operations, Regulation FD disclosure
|
May 11, 2026 | May 11, 2026 |
| ARS | Annual report to shareholders | Apr 27, 2026 | Dec 31, 2025 |
| DEFA14A | Additional proxy material | Apr 27, 2026 | — |
| DEF 14A | Proxy statement | Apr 27, 2026 | Apr 21, 2026 |
| 4 | Insider transaction | Apr 3, 2026 | Apr 1, 2026 |
| 4 | Insider transaction | Apr 3, 2026 | Apr 1, 2026 |
| 4 | Insider transaction | Apr 3, 2026 | Apr 1, 2026 |
| 4 | Insider transaction | Mar 9, 2026 | Mar 5, 2026 |
| 4 | Insider transaction | Mar 9, 2026 | Mar 5, 2026 |
| 4 | Insider transaction | Mar 9, 2026 | Dec 5, 2025 |
| S-8 | Employee stock plan registration | Mar 5, 2026 | — |
| 10-K | Annual report | Mar 5, 2026 | Dec 31, 2025 |
| 8-K |
Current report
Results of operations
|
Mar 5, 2026 | Mar 5, 2026 |
| 8-K |
Current report
Bylaw or fiscal year change, Regulation FD disclosure
|
Jan 12, 2026 | Jan 12, 2026 |
| 4 | Insider transaction | Dec 8, 2025 | Dec 5, 2025 |
| 4 | Insider transaction | Dec 8, 2025 | Dec 5, 2025 |
| 4 | Insider transaction | Dec 8, 2025 | Dec 5, 2025 |
| 4 | Insider transaction | Dec 8, 2025 | Dec 5, 2025 |
| 4 | Insider transaction | Dec 1, 2025 | Sep 5, 2025 |
| 4 | Insider transaction | Dec 1, 2025 | Sep 5, 2025 |
| 4 | Insider transaction | Dec 1, 2025 | Sep 5, 2025 |
| 4 | Insider transaction | Dec 1, 2025 | Sep 5, 2025 |
| 10-Q | Quarterly report | Nov 12, 2025 | Sep 30, 2025 |
| 8-K |
Current report
Results of operations, Regulation FD disclosure
|
Nov 12, 2025 | Nov 11, 2025 |
| 8-K |
Current report
Material agreement, Agreement ended
|
Oct 1, 2025 | Sep 29, 2025 |
| 144 | Notice of proposed sale | Sep 11, 2025 | — |
| 4 | Insider transaction | Sep 2, 2025 | Sep 2, 2025 |
| 3 | Initial insider ownership | Aug 15, 2025 | Aug 11, 2025 |
| 10-Q | Quarterly report | Aug 12, 2025 | Jun 30, 2025 |
| 8-K |
Current report
Results of operations, Regulation FD disclosure
|
Aug 12, 2025 | Aug 12, 2025 |
| 144 | Notice of proposed sale | Jul 9, 2025 | — |
| 4 | Insider transaction | Jun 12, 2025 | Jun 10, 2025 |
| 4 | Insider transaction | Jun 12, 2025 | Jun 10, 2025 |
| 4 | Insider transaction | Jun 12, 2025 | Jun 10, 2025 |
| 8-K |
Current report
Shareholder vote results
|
Jun 11, 2025 | Jun 10, 2025 |
| 4 | Insider transaction | Jun 9, 2025 | Jun 6, 2025 |
| 4 | Insider transaction | Jun 9, 2025 | Jun 6, 2025 |
| 4 | Insider transaction | Jun 9, 2025 | Jun 6, 2025 |
| 4 | Insider transaction | Jun 9, 2025 | Jun 6, 2025 |
| 4 | Insider transaction | Jun 9, 2025 | Jun 6, 2025 |
| 8-K |
Current report
Other events
|
May 14, 2025 | May 14, 2025 |
| 10-Q | Quarterly report | May 13, 2025 | Mar 31, 2025 |
| 8-K |
Current report
Results of operations, Regulation FD disclosure
|
May 13, 2025 | May 13, 2025 |
| ARS | Annual report to shareholders | Apr 28, 2025 | Dec 31, 2024 |
| DEFA14A | Additional proxy material | Apr 28, 2025 | — |
| DEF 14A | Proxy statement | Apr 28, 2025 | Apr 25, 2025 |
| 4 | Insider transaction | Apr 3, 2025 | Apr 1, 2025 |
| 4 | Insider transaction | Apr 3, 2025 | Apr 1, 2025 |
| 4 | Insider transaction | Apr 3, 2025 | Apr 1, 2025 |
| 4 | Insider transaction | Apr 3, 2025 | Apr 1, 2025 |
| 4 | Insider transaction | Apr 3, 2025 | Apr 1, 2025 |
| EFFECT | Filing | Mar 25, 2025 | — |
| CORRESP | Letter to the SEC | Mar 21, 2025 | — |
| UPLOAD | Letter from the SEC | Mar 21, 2025 | — |
| 8-K |
Current report
Material agreement
|
Mar 17, 2025 | Mar 17, 2025 |
| S-3 | Shelf registration | Mar 17, 2025 | — |
| S-8 | Employee stock plan registration | Mar 17, 2025 | — |
| 8-K |
Current report
Results of operations, Regulation FD disclosure
|
Mar 17, 2025 | Mar 17, 2025 |
| 10-K | Annual report | Mar 17, 2025 | Dec 31, 2024 |
| 4 | Insider transaction | Mar 7, 2025 | Mar 5, 2025 |
| 4 | Insider transaction | Mar 7, 2025 | Mar 5, 2025 |
| 4 | Insider transaction | Feb 5, 2025 | Feb 3, 2025 |
| 3 | Initial insider ownership | Jan 27, 2025 | Jan 27, 2025 |
| 8-K |
Current report
Officer or director change, Regulation FD disclosure
|
Jan 16, 2025 | Jan 13, 2025 |
| 8-K |
Current report
Other events
|
Dec 10, 2024 | Dec 9, 2024 |
| 4 | Insider transaction | Dec 6, 2024 | Dec 5, 2024 |
| 8-K |
Current report
Results of operations
|
Nov 13, 2024 | Nov 13, 2024 |
| 10-Q | Quarterly report | Nov 13, 2024 | Sep 30, 2024 |
| SC 13G | Ownership over 5% (passive) | Nov 6, 2024 | — |
| 4 | Insider transaction | Sep 6, 2024 | Sep 5, 2024 |
| 8-K |
Current report
Other events
|
Sep 3, 2024 | Sep 3, 2024 |
| 8-K |
Current report
Results of operations
|
Aug 14, 2024 | Aug 14, 2024 |
| 10-Q | Quarterly report | Aug 14, 2024 | Jun 30, 2024 |
| 8-K |
Current report
Results of operations, Regulation FD disclosure
|
May 14, 2024 | May 14, 2024 |
| 10-Q | Quarterly report | May 14, 2024 | Mar 31, 2024 |
| SC 13G | Ownership over 5% (passive) | May 10, 2024 | — |
| 8-K |
Current report
Agreement ended, Results of operations, Regulation FD disclosure
|
May 1, 2024 | Apr 26, 2024 |
| 4 | Insider transaction | Apr 3, 2024 | Apr 1, 2024 |
| 4 | Insider transaction | Apr 3, 2024 | Apr 1, 2024 |
| 4 | Insider transaction | Apr 3, 2024 | Apr 1, 2024 |
| 4 | Insider transaction | Apr 3, 2024 | Apr 1, 2024 |
| 4 | Insider transaction | Apr 3, 2024 | Apr 1, 2024 |
| 4 | Insider transaction | Apr 3, 2024 | Apr 1, 2024 |
| 4 | Insider transaction | Apr 3, 2024 | Apr 1, 2024 |
| 4 | Insider transaction | Apr 3, 2024 | Apr 1, 2024 |
| 4 | Insider transaction | Apr 3, 2024 | Apr 1, 2024 |
| 4 | Insider transaction | Apr 3, 2024 | Apr 1, 2024 |
| 4 | Insider transaction | Apr 3, 2024 | Apr 1, 2024 |
| 8-K |
Current report
Results of operations
|
Mar 27, 2024 | Mar 27, 2024 |
| 10-K | Annual report | Mar 27, 2024 | Dec 31, 2023 |
| 4 | Insider transaction | Feb 15, 2024 | Feb 9, 2024 |
| 4 | Insider transaction | Feb 15, 2024 | Feb 13, 2024 |
| 3 | Initial insider ownership | Feb 15, 2024 | Feb 8, 2024 |
| 4 | Insider transaction | Feb 14, 2024 | Feb 13, 2024 |
| 8-K |
Current report
Bylaw or fiscal year change
|
Feb 13, 2024 | Feb 13, 2024 |
| 424B4 | Prospectus | Feb 12, 2024 | — |
| S-8 | Employee stock plan registration | Feb 9, 2024 | — |
| SEC STAFF LETTER | Filing | Feb 8, 2024 | — |
| EFFECT | Filing | Feb 8, 2024 | — |
| 3 | Initial insider ownership | Feb 8, 2024 | Feb 8, 2024 |
| 3 | Initial insider ownership | Feb 8, 2024 | Feb 8, 2024 |
| 3 | Initial insider ownership | Feb 8, 2024 | Feb 8, 2024 |
| 3 | Initial insider ownership | Feb 8, 2024 | Feb 8, 2024 |
| 3 | Initial insider ownership | Feb 8, 2024 | Feb 8, 2024 |
| 3 | Initial insider ownership | Feb 8, 2024 | Feb 8, 2024 |
| 3 | Initial insider ownership | Feb 8, 2024 | Feb 8, 2024 |
| 3 | Initial insider ownership | Feb 8, 2024 | Feb 8, 2024 |
| 3 | Initial insider ownership | Feb 8, 2024 | Feb 8, 2024 |
| 3 | Initial insider ownership | Feb 8, 2024 | Feb 8, 2024 |
| 3 | Initial insider ownership | Feb 8, 2024 | Feb 8, 2024 |
| 3 | Initial insider ownership | Feb 8, 2024 | Feb 8, 2024 |
| CERT | Filing | Feb 8, 2024 | — |
| CORRESP | Letter to the SEC | Feb 7, 2024 | — |
| S-1/A | Amended registration statement | Feb 7, 2024 | — |
| UPLOAD | Letter from the SEC | Feb 6, 2024 | — |
| CORRESP | Letter to the SEC | Feb 6, 2024 | — |
| CORRESP | Letter to the SEC | Feb 6, 2024 | — |
| 8-A12B | Filing | Feb 5, 2024 | — |
| CORRESP | Letter to the SEC | Feb 5, 2024 | — |
| S-1/A | Amended registration statement | Feb 5, 2024 | — |
| CORRESP | Letter to the SEC | Jan 18, 2024 | — |
| CORRESP | Letter to the SEC | Jan 16, 2024 | — |
| S-1/A | Amended registration statement | Jan 8, 2024 | — |
| CORRESP | Letter to the SEC | Jan 5, 2024 | — |
| S-1 | Registration statement | Jan 5, 2024 | — |
| UPLOAD | Letter from the SEC | Dec 20, 2023 | — |
| DRS/A | Filing | Dec 11, 2023 | — |
| SEC STAFF LETTER | Filing | Sep 18, 2023 | — |
| DRSLTR | Filing | Sep 7, 2023 | — |
| DRS/A | Filing | Sep 7, 2023 | — |
| UPLOAD | Letter from the SEC | Aug 31, 2023 | — |
| DRS | Filing | Aug 3, 2023 | — |
| D | Filing | Jan 11, 2023 | — |
| D | Filing | Feb 7, 2022 | — |
| D | Filing | Mar 29, 2021 | — |
| D | Filing | Nov 25, 2020 | — |
| D | Filing | Aug 16, 2019 | — |
Showing 154 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Biological Products, (No Diagnostic Substances) (SIC 2836)
- Listed as
- MGX (Nasdaq)
- Fiscal year ends
- December 31
- Headquarters
- Emeryville, CA
- SEC filer status
- , Emerging growth company
- SEC CIK
- 1785279
- Former names
- Metagenomi, Inc. (until Jan 12, 2026); Metagenomi Technologies, LLC (until Jan 18, 2024)
Other Biological Products, (No Diagnostic Substances) companies
- Amgen Inc AMGN
- Gilead Sciences, Inc. GILD
- Moderna, Inc. MRNA
- Argenx SE ARGX
- Revolution Medicines, Inc. RVMD
- Biogen Inc. BIIB
- BioNTech SE BNTX
- Exelixis, Inc. EXEL
All 182 Biological Products, (No Diagnostic Substances) companies
Source: SEC EDGAR filings. This is company-reported data, not investment advice.